Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Patients with Rosacea have Increased Risk of Dementia
Ann Neurol 79:921-928, Egeberg, A.,et al, 2016
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Benzodiazepine Use and Risk of Alzheimers Disease: Case-Control Study
BMJ 349:g5205, Billioti deGage, S.,et al, 2014
Fracture as an Independent Risk Factor of Dementia
Medicine 93:e188, Tsai, C.H.,et al, 2014
TREM2 Variants in Alzheimers Disease
NEJM 368:117-127, Guerreiro, R.,et al, 2013
Variant of TREM2 Associated with the Risk of Alzheimers Disease
NEJM 368:107-116, Jonsson, T.,et al, 2013
Variant TREM2 as Risk Factor for Alzheimers Disease
NEJM 368:182-184, Neumann, H. & Daly, M., 2013
Is There a Link Between Open-Angle Glaucoma and Dementia?: The Three-City-Alienor Cohort
Ann Neurol 74:171-179, Helmer, C.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Inverse Association between Cancer and Alzheimers Disease: Results from the Framingham Heart Study
BMJ 344:e1442, Driver,J.A.,et al, 2012
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
Practice Parameter Update: Evaluation and Management of Driving Risk in Dementia: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:1316-1324, Iverson,D.J., et al, 2010
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
Association Between Mid-Life Martial Status and Cognitive Function in Later Life: Population Based Cohort Study
BMJ 339:99,57, H�kansson,K.,et al, 2009
Disclosure of APOE Genotype for Risk of Alzheimers Disease
NEJM 361:245-254,298, Green,R.C.,et al, 2009
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Predicting the Time of Conversion to MCI in the Elderly: Role of Verbal Expression and Learning
Neurol 73:1436-1442, 1432, Oulhaj,A.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Joint Effect of Stroke and APOE 4 on Dementia Risk: The Canadian Study of Health and Aging
Neurol 70:9-16,5, Jin,Y.P.,et al, 2008
Conjugal Alzheimer Disease: Risk in Children When Both Parents Have Alzheimer Disease
Arch Neurol 65:373-378, Jayadev,S.,et al, 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Relation Between Smoking and Risk of Dementia and Alzheimer Disease: The Rotterdam Study
Neurol 69:998-1005, Reitz,C.,et al, 2007
Mild Cognitive Impariment is Early-Stage Alzheimer Disease
Arch Neurol 63:15-16, Morris,J.C., 2006
Mild Cognitive Impairment
Lancet 367:1262-1270, Gauthier,S.,et al, 2006
Bone Mineral Density and the Risk of Alzheimer Disease
Arch Neurol 62:107-111, Tan,Z.S.,et al, 2005
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function
Arch Neurol 61:661-666, Arvanitakis,Z.,et al, 2004
Hyperinsulinemia and Risk of Alzheimer Disease
Neurol 63:1187-1192, Luchsinger,J.A.,et al, 2004
Low Blood Pressure and Risk of Dementia in the Kungsholmen Project
Arch Neurol 60:223-228, Qiu,C.,et al, 2003
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Leisure Activities and the Risk of Dementia in the Elderly
NEJM 348:2508-2516, Verghese,J.,et al, 2003
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
NEJM 346:476-483, 466, Seshadri,S.,et al, 2002
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Hormone Replacement Therapy and Cognition
JAMA 285:1489-1499, LeBlanc,E.S.,et al, 2001